/ Not yet recruiting临床2期IIT Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ccRCC.
A Phase 2 Study of Ivonescimab (Bispecific Antibody Against PD1 and VEGF) For the Treatment of Endometrial (EC) and Cervical (CC) Cancers
The researchers are doing this study to find out if ivonescimab is an effective treatment for people with endometrial cancer (EC) and/or cervical cancer (CC). The researchers will also look at whether the study drug is safe and causes few or mild side effects in participants.
100 项与 Summit Therapeutics Sub, Inc. 相关的临床结果
0 项与 Summit Therapeutics Sub, Inc. 相关的专利(医药)
100 项与 Summit Therapeutics Sub, Inc. 相关的药物交易
100 项与 Summit Therapeutics Sub, Inc. 相关的转化医学